Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments

  title={Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments},
  author={Jonas Bech M\oller and Rune Viig Overgaard and Maria Kjellsson and N R Kristensen and S\oren Klim and S H Ingwersen and M O Karlsson},
  booktitle={CPT: pharmacometrics & systems pharmacology},
Late-phase clinical trials within diabetes generally have a duration of 12-24 weeks, where 12 weeks may be too short to reach steady-state glycated hemoglobin (HbA1c). The main determinant for HbA1c is blood glucose, which reaches steady state much sooner. In spite of this, few publications have used individual data to assess the time course of both glucose and HbA1c, for predicting HbA1c. In this paper, we present an approach for predicting HbA1c at end-of-trial (24-28 weeks) using glucose and… CONTINUE READING
5 Citations
25 References
Similar Papers


Publications referenced by this paper.
Showing 1-10 of 25 references

competitive landscape for oral non-insulin therapies in type 2 diabetes

  • Samtani, M. N. Simple pharmacometric tools for oral anti-diabe development
  • Biopharm. Drug Dispos. 31, 162–177
  • 2010

Efficacy and safety of the human glucagonlike peptide1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes ( LEAD4 Met + TZD )

  • B. Zinman
  • Diabetes Care
  • 2009

Nonmem User ́s Guides (1989–2009) (Icon Development Solutions

  • S. Beal, L. B. Sheiner, A. Boeckmann, R. J. Bauer
  • Ellicott City, MD,
  • 2009

the LEAD (liraglutide effect and action in diabetes)-2 study

  • M. et al. Nauck, LEAD-2 Study Group. Efficacy, glimepiride safety comparison of liraglutide, all in combination with metformin in type 2 diabetes placebo
  • Diabetes Care 32, 84–90
  • 2009

Similar Papers

Loading similar papers…